help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nakai, Y.
Right arrow Articles by Kurimoto, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nakai, Y.
Right arrow Articles by Kurimoto, F.
The Journal of Clinical Endocrinology & Metabolism Vol. 84, No. 4 1226-1228
Copyright © 1999 by The Endocrine Society


Original Studies

Plasma Concentrations of Tumor Necrosis Factor-{alpha} (TNF-{alpha}) and Soluble TNF Receptors in Patients with Anorexia Nervosa1

Yoshikatsu Nakai, Seiji Hamagaki, Ryuro Takagi, Ataru Taniguchi and Fumihiko Kurimoto

College of Medical Technology (Y.N.) and Department of Psychiatry (S.H.) Kyoto University, Kyoto 606-8507; Takagi Psychiatric Clinic (R.T.), Kyoto 606-8507; Kansai-Denryoku-Hospital (A.T.), Osaka 553-0003; and Mitsubishi Kagaku Bio-Clinical Laboratory Inc. (F.K.), Tokyo 174-0056, Japan

Address all correspondence and requests for reprints to: Yoshikatsu Nakai, M.D., College of Medical Technology, Kyoto University, 53 Kawaharacho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan. E-mail: YN{at}itan.kyoto-u.ac.jp


    Abstract
 Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
 References
 
Tumor necrosis factor-{alpha} (TNF-{alpha}) is a cytokine with numerous immunological and metabolic activities. To study the role of TNF-{alpha} on the pathophysiology of anorexia nervosa and its complications, plasma concentrations of TNF-{alpha}, 2 soluble TNF receptors (sTNF-RI and sTNF-RII), and leptin were measured in 20 female patients with anorexia nervosa (AN) and 20 age-matched normal women (N). Plasma TNF-{alpha} concentrations in AN were significantly higher than those in N (4.1 ± 0.6 pg/mL vs. 1.6 ± 0.1 pg/mL; P < 0.01). Although no significant difference was observed in plasma sTNF-RI concentrations between the two groups, plasma sTNF-RII concentrations in AN were significantly higher than those in N (2094.0 ± 138.5 pg/mL vs. 1569.5 ± 84.0 pg/mL; P < 0.01). Plasma concentrations of TNF-{alpha} and sTNF-RII after treatment of 8 anorectic patients were not different from those before treatment, although body fat mass and plasma leptin concentrations significantly increased after treatment. Plasma TNF-{alpha} concentrations were not related to body fat mass in anorectic patients. These results suggest that the adipose tissue may not be the immediate source of TNF-{alpha} in anorectic patients and that TNF-{alpha} may contribute to the pathophysiology of immunological and metabolic abnormalities in anorexia nervosa. .


    Introduction
 Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
 References
 
ANOREXIA NERVOSA, a common illness among females in late adolescence and early adulthood, is a syndrome characterized by severe weight loss and obsessive fear of being fat (1). Unfortunately, the pathogenesis of this potentially fatal illness remains poorly understood. Many endocrine abnormalities in anorexia nervosa have been reported (1, 2), but few studies on immunological disturbances have been performed, and results are controversial (3, 4, 5). Cytokines released from immune cells may play an important role in communication between the immune system and the central nervous system (6). Thus, cytokines might play important roles in the etiology of anorexia nervosa and/or the pathogenesis of the associated medical complications.

Tumor necrosis factor-{alpha} (TNF-{alpha}), also known as cachectin, is a cytokine with numerous immunological and metabolic activities. Of particular interest is its ability to mediate weight loss in experimental animals by several mechanisms including suppression of food intake, suppression of lipoprotein lipase, and catabolic effects on energy storage tissues (7). However, the effect of TNF-{alpha} in mediating cachexia in cancer and in chronic infections in humans has not yet been unequivocally demonstrated (8, 9). Using available assays, number of papers were published concerning the lack of reliability of TNF-{alpha} measurements in plasma and the relationship of bioassay to immunoassay (7, 9).

There are two TNF-{alpha} receptors: TNF-RI (55kDa) and TNF-RII (75kDa) (10). Soluble forms of the two TNF-{alpha} receptors (sTNF-RI and sTNF-RII), which represent the extracellular portions of membrane-associated TNF-{alpha} receptors, have been identified in serum and urine and play a role as modulators of the biological function of TNF-{alpha} in an agonist/antagonist pattern (11). Because injection of TNF-{alpha} results in increased shedding of TNF-{alpha} receptors, it is likely that TNF-{alpha} release is reflected by sTNF-R levels (12). The measurement of sTNF-R may therefore be critically important, not only with respect to the validity of the particular assay used, but in the interpretation of accompanying TNF-{alpha} levels (9).

Schattner et al. (13) found increased spontaneous production of TNF-{alpha} in vitro by peripheral blood mononuclear cells from patients with anorexia nervosa. However, TNF-{alpha} production after stimulation of peripheral blood mononuclear cells by phytohemagglutinin was not different from controls. Furthermore, spontaneous TNF-{alpha} production in vitro was in the normal range in the chronically undernourished subjects (14). There were only two reports, to our knowledge, that plasma TNF-{alpha} concentrations were measured in anorexia nervosa. Plasma TNF-{alpha} was not detected in both anorectic patients and control subjects in these reports (13, 15). There was no report about plasma sTNF-R concentrations in anorexia nervosa.

Based on the above, it is natural to question whether the anorectic patients have a higher-than-normal concentrations of TNF-{alpha} and sTNF-R in plasma, and TNF-{alpha} may play some role in the pathophysiology of anorexia nervosa and its complications. In the present study, therefore, we measured plasma concentrations of TNF-{alpha}, sTNF-RI, and sTNF-RII with sensitive assays in female patients with anorexia nervosa and in normal control women.


    Subjects and Methods
 Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
 References
 
Subjects

The study subjects were 20 female patients with anorexia nervosa and 20 healthy women. All the untreated anorectic patients who visited our clinic were used for the study except those who had concurrently bulimia nervosa. A diagnosis of anorexia nervosa and bulimia nervosa was made according to the criteria of DSM-IV (1). The duration of the illness was 45.0 ± 9.6 (mean ± SEM) months. Eight of 20 anorectic patients were restudied after achievement of goal body mass index (BMI) (more than 18.0 kg/m2). All patients were treated with cognitive-behavioral approach. The duration of the treatment was 7.4 ± 1.2 months. Control subjects were age-matched healthy women whose BMI was in the range of 18.0–22.0 kg/m2. All anorectic patients before and after the treatment with amenorrheic, and controls were studied in the follicular phase of the menstrual cycle. None of them had any associated illness, nor were they receiving any medications when studied. There were no infectious complications throughout the study. All gave their informed consent for the study.

Methods

A blood sample was collected from each subject while fasting, and plasma was frozen until analysis. Plasma TNF-{alpha} concentrations were measured by enzyme immunoassay kit (Quantikine HS Human TNF-{alpha} immunoassay kit, R & D Systems, Inc, Minneapolis, MN). The limit of sensitivity was 0.50 pg/mL, the intraassay coefficient of variation was 6.3%, and the interassay coefficient of variation was 7.6%. Plasma concentrations of sTNF-RI and sTNF-RII were measured by enzyme-linked immunosorbent assay (ELISA) (BIOTRAK, Amersham Life Science, Uppsala, Sweden). The limits of sensitivity for sTNF-RI and sTNF-RII were 25 pg/mL and 50 pg/mL, respectively. Intraassay coefficient of variation and interassay coefficient of variation for both assays were less than 5% and less than 7%, respectively. Plasma leptin concentrations were measured by RIA using commercial kits (Human Leptin RIA kit, Linco Research Inc., St. Charles, MO). The limit of sensitivity was 0.5 ng/mL, the intraassay coefficient of variation was 3.5%, and the interassay coefficient of variation was 2.3%. Body fat mass was determined by multiplying the percent of body fat by the body weight. The percent of body fat was determined from bioelectric impedance analysis, a method that has been validated (16).

Results are expressed as mean ± SEM. The significance of difference was tested with Student’s t test for paired or unpaired data, with the level of statistical significance at P < 0.05. Plasma concentrations of leptin and TNF-{alpha} were log transformed to normalize the distribution, respectively. Linear regression analysis was used to assess the degree of association between various indices. All calculations were performed using Statview version 4.5 (Abacus Concepts Inc., Berkley, CA).


    Results
 Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
 References
 
BMI was significantly lower in 20 anorectic patients than in 20 normal controls (13.7 ± 0.4 kg/m2 vs. 19.9 ± 0.2 kg/m2; P < 0.01). Body fat mass was also significantly lower in anorectic patients than in controls (2.9 ± 0.3 kg vs. 12.3 ± 0.4 kg; P < 0.01). No significant difference was observed in age between the two groups (22.1 ± 1.0 yr vs. 20.2 ± 0.3 yr).

Results in plasma concentrations of TNF-{alpha}, sTNF-RI, sTNF-RII, and leptin in 20 normal controls and 20 anorectic patients are depicted in Fig. 1Go. Plasma TNF-{alpha} concentrations were significantly higher in 20 anorectic patients than in 20 controls (4.1 ± 0.6 pg/mL vs. 1.6 ± 0.1 pg/mL; P < 0.01). No significant difference was observed in plasma sTNF-RI concentrations between the two groups (566.9 ± 45.3 pg/mL vs. 611.6 ± 26.6 pg/mL). Plasma sTNF-RII concentrations were significantly higher in anorectic patients than in controls (2094.0 ± 138.5 pg/mL vs. 1569.5 ± 84.0 pg/mL; P < 0.01). Plasma leptin concentrations were significantly lower in anorectic patients than in controls (1.7 ± 0.1 ng/mL vs. 6.5 ± 0.5 ng/mL; P < 0.01). Plasma leptin concentrations were significantly related to body fat mass (r = 0.805, P < 0.01) or to BMI (r = 0.780, P < 0.01) in anorectic patients. However, plasma concentrations of TNF-{alpha}, sTNF-RI, and sTNF-RII were not related to plasma leptin concentrations or to body fat mass in these patients, respectively.



View larger version (21K):
[in this window]
[in a new window]
 
Figure 1. Plasma concentrations of TNF-{alpha}, sTNF-RI, sTNF-RII, and leptin in 20 normal control women (N) and 20 female patients with anorexia nervosa (AN). *, AN significantly different from N, P < 0.01.

 
After the treatment period in eight anorectic patients, the body fat mass increased from 3.8 ± 0.5 kg to 9.7 ± 0.7 kg (P < 0.01) and BMI increased from 14.8 ± 0.7 kg/m2 to 18.7 ± 0.5 kg/m2 (P < 0.01). Plasma leptin concentrations increased from 1.7 ± 0.2 ng/mL to 6.1 ± 0.9 ng/mL (P < 0.01). However, plasma TNF-{alpha} concentrations after were not significantly different from those before the treatment (4.5 ± 0.7 pg/mL vs. 4.1 ± 0.8 pg/mL). Plasma sTNF-RII concentrations after were not significantly different from those before the treatment (1945.0 ± 152.2 pg/mL vs. 1940.0 ± 190.6 pg/mL) (Fig. 2Go).



View larger version (23K):
[in this window]
[in a new window]
 
Figure 2. Body fat mass and plasma concentrations of TNF-{alpha}, sTNF-RII, and leptin before and after the treatment of 8 patients with anorexia nervosa. Body fat mass and plasma leptin concentrations were significantly different between before- and after-treatments in these patients (*, P < 0.01). On the other hand, plasma concentrations of TNF-{alpha} and sTNF-RII were not significantly different between before- and after-treatments.

 

    Discussion
 Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
 References
 
Our data show for the first time that plasma TNF-{alpha} concentrations were significantly higher in anorectic patients than in normal controls (Fig. 1Go). Our present results are consonant with the previous findings by Schattner et al. (13) that anorectic patients had increased spontaneous production of TNF-{alpha} by peripheral blood mononuclear cells in vitro. TNF-{alpha} is mainly produced by stimulated monocytes, macrophages, and T-lymphocyte subsets in response to bacterial toxines, inflammatory products, and other invasive stimuli (7). It has recently been demonstrated that TNF-{alpha} is constitutively expressed by adipose tissue (17). Obesity is associated with increased plasma TNF-{alpha} concentrations (18), and TNF-{alpha} may be a mediator of insulin resistance (17). We have no direct evidence for the source of plasma TNF-{alpha} in anorectic patients. However, the adipose tissue may not be the immediate source of TNF-{alpha} in these patients, because plasma TNF-{alpha} concentrations are not related to body fat mass.

Furthermore, plasma TNF-{alpha} concentrations after treatment were not significantly different from those before treatment in 8 anorectic patients, although body fat mass and plasma leptin concentrations were significantly increased after the treatment in these patients (Fig. 2Go). After successful nutritional repletion in anorectic patients, the changes in cell-mediated cytotoxicity and TNF-{alpha} production in vitro were reversed in the studies by Vaisman et al. (14, 19). The discrepancy between the studies by Vaisman et al. and ours may be attributable to the different methods; in vitro vs. in vivo (20).

The biological and metabolic effects of TNF-{alpha} have been studied. In general, acute exposure to high doses of TNF-{alpha} results in shock and tissue injury virtually indistinguishable from septic shock syndrome. On the other hand, chronic TNF-exposure causes the development of cachexia characterized by anorexia, weight loss, and depletion of whole-body protein and lipid (7). Therefore, our present findings suggest that TNF-{alpha} may play some role for the metabolic abnormalities in anorectic patients.

Meanwhile, TNF-{alpha} is a pivotal mediator of inflammation that activates leukocytes, enhances adherence of neutrophils and monocytes to endothelium, promotes migration of inflammatory cells into the intercellular matrix, and triggers local production of other proinflammatory cytokines (7). Furthermore, the experiments with mice deficient in TNF-{alpha} suggest that TNF-{alpha} is a potent anti-inflammatory cytokine (21, 22). These cytokines have been implicated in the beneficial effects of TNF-{alpha}; TNF-{alpha} may modify the impaired immune function in anorectic patients (3, 13).

In the present study plasma concentrations of sTNF-RII in anorectic patients were significantly higher than those in normal controls, whereas no significant difference was observed in plasma sTNF-RI concentrations between the two groups (Fig. 1Go). A variety of stimuli trigger the shedding of sTNF-R from the cell surface into the circulation through proteolytic processing (11). Available evidence suggests that plasma sTNF-R concentrations are a sensitive indicator of activation of the TNF-{alpha} system (9, 11, 12). The majority of biological responses classically attributed to TNF-{alpha} are mediated by TNF-RI. However, the recent studies using mice lacking one or both TNF receptors suggest a dominant role of TNF-RII in suppressing TNF-mediated inflammatory responses (23). To elucidate the significance of the elevated plasma sTNF-RII concentrations in anorectic patients, further investigation is needed.

In summary, plasma concentrations of TNF-{alpha} and sTNF-RII are significantly higher in anorectic patients than in normal controls. These concentrations remain altered in anorectic patients even after weight restoration. Plasma TNF-{alpha} concentrations were not related to body fat mass in anorectic patients. These results suggest that the adipose tissue may not be the immediate source of TNF-{alpha} in anorectic patients and that TNF-{alpha} may contribute to the pathophysiology of immunological and metabolic abnormalities in anorexia nervosa.


    Acknowledgments
 
We greatly appreciate the secretarial help of Miss Hitomi Kawamura.


    Footnotes
 
1 This work was supported by a grant from the Ministry of Health and Welfare of Japan and Grant Medical Research from Smoking Research Foundation in Japan. Back

Received September 15, 1998.

Revised December 17, 1998.

Accepted January 4, 1999.


    References
 Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
 References
 

  1. American Psychiatric Association. 1994 Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, D.C.: American Psychiatric Press.
  2. Kaye WH, Gendall K, Kye C. 1998 The role of the central nervous system in the psychoneuroendocrine disturbances of anorexia and bulimia nervosa. Psychiatr Clin North Am. 21:381–396.[CrossRef][Medline]
  3. Pomeroy C, Mitchell JE, Eckert ED. 1992 Risk of infection and immune function in anorexia nervosa. Int J Eat Disord. 12:47–55.
  4. Marcos A, Varela P, Toro O, et al. 1997 Interactions between nutrition and immunity in anorexia nervosa: a 1-y follow-up study. Am J Clin Nutr. 66:485S–490S.
  5. Mustafa A, Ward A, Treasure J, Peakman M. 1997 T lymphocyte subpopulations in anorexia nervosa and refeeding. Clin Immunol Immunopathol. 82:282–289.[CrossRef][Medline]
  6. Sternberg EM. 1998 Introduction: overview of the conference and the field. Ann NY Acad Sci. 840:1–8.[CrossRef][Medline]
  7. Tracey KJ, Cerami A. 1994 Tumor necrosis factor: A pleiotropic cytokine and therapeutic target. Annu Rev Med. 45:491–503.[CrossRef][Medline]
  8. Oliff A. 1988 The role of tumor necrosis factor (cachectin) in cachexia. Cell. 54:141–142.[CrossRef][Medline]
  9. Heney D, Whicher JT. 1995 Factors affecting the measurement of cytokines in biological fluids: implications for their clinical measurement. Ann Clin Biochem. 32:358–368.
  10. Vandenabeele P, Declercq W, Beyaert R, Fiers W. 1995 Two tumor necrosis factor receptors: structure and function. Trends Cell Biol. 5:392–399.[CrossRef][Medline]
  11. Diez-Ruiz A, Tilz GP, Zangerle R, Baier-Bitterlich G, Wachter H, Fuchs D. 1995 Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis. Eur J Haematol. 54:1–8.[Medline]
  12. Lantz M, Malik S, Slevin ML, Olsson I. 1990 Infusion of tumor necrosis factor (TNF) causes an increase in circulating TNF-binding protein in humans. Cytokine. 2:402–406.[CrossRef][Medline]
  13. Schattner A, Steinbock M, Tepper R, Schonfeld A, Vaisman N, Hahn T. 1990 Tumor necrosis factor production and cell-mediated immunity in anorexia nervosa. Clin Exp Immunol. 79:62–66.[Medline]
  14. Vaisman N, Hahn T. 1991 Tumor necrosis factor-{alpha} and anorexia—cause or effect? Metabolism. 40:720–723.[CrossRef][Medline]
  15. Pomeroy C, Eckert E, Hu S, et al. 1994 Role of interleukin-6 and transforming growth factor-ß in anorexia nervosa. Biol Psychiatry. 36:836–839.[CrossRef][Medline]
  16. Nakadomo F, Tanaka K, Hazama T, Maeda K. 1990 Assessment of body composition in Japanese females by bioelectrical impedance analysis. Jpn Appl Phys Fitness Sports Med. 39:164–172.
  17. Hotamisligil GS, Shargill NS, Spiegelman BM. 1993 Adipose expression of tumor necrosis factor-{alpha}: direct role in obesity-linked insulin resistance. Science. 259:87–91.[Abstract/Free Full Text]
  18. Dandona P, Weinstock R, Thusu K, Abdel-Rahman E, Aljada A, Wadeen T. 1998 Tumor necrosis factor-{alpha} in sera of obese patients: fall with weight loss. J Clin Endocrinol Metab. 83:2907–2910.[Abstract/Free Full Text]
  19. Vaisman N, Hahn T, Dayan Y, Schattner A. 1990 The effect of different nutritional states on cell-mediated cytotoxicity. Immunol Lett. 24:37–41.[CrossRef][Medline]
  20. Gleeson M. 1998 Are circulating cytokine receptors and ex vivo interleukin-1 receptor antagonist and interleukin-1 production increased and tumour necrosis factor-{alpha} production decreased after a 5-km run? Eur J Clin Invest. 28:873–874.[CrossRef][Medline]
  21. Marino MW, Dunn A, Grail D, et al. 1997 Characterization of tumor necrosis factor-deficient mice. Proc Natl Acad Sci USA. 94:8093–8098.[Abstract/Free Full Text]
  22. Liu J, Marino MW, Wong G, et al. 1998 TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination. Nat Med. 4:78–83.[CrossRef][Medline]
  23. Peschon JJ, Torrance DS, Stocking KL, et al. 1998 TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. J Immunol. 160:943–952.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
F. M. H. van Dielen, W. A. Buurman, M. Hadfoune, J. Nijhuis, and J. W. Greve
Macrophage Inhibitory Factor, Plasminogen Activator Inhibitor-1, Other Acute Phase Proteins, and Inflammatory Mediators Normalize as a Result of Weight Loss in Morbidly Obese Subjects Treated with Gastric Restrictive Surgery
J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 4062 - 4068.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
T. Tagami, N. Satoh, T. Usui, K. Yamada, A. Shimatsu, and H. Kuzuya
Adiponectin in Anorexia Nervosa and Bulimia Nervosa
J. Clin. Endocrinol. Metab., April 1, 2004; 89(4): 1833 - 1837.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
N. Pannacciulli, R. Vettor, G. Milan, M. Granzotto, A. Catucci, G. Federspil, P. De Giacomo, R. Giorgino, and G. De Pergola
Anorexia Nervosa Is Characterized by Increased Adiponectin Plasma Levels and Reduced Nonoxidative Glucose Metabolism
J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1748 - 1752.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
M. Hotta, I. Fukuda, K. Sato, N. Hizuka, T. Shibasaki, and K. Takano
The Relationship between Bone Turnover and Body Weight, Serum Insulin-Like Growth Factor (IGF) I, and Serum IGF-Binding Protein Levels in Patients with Anorexia Nervosa
J. Clin. Endocrinol. Metab., January 1, 2000; 85(1): 200 - 206.
[Abstract] [Full Text]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nakai, Y.
Right arrow Articles by Kurimoto, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nakai, Y.
Right arrow Articles by Kurimoto, F.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals